Abstract
Background. The monoclonal antibody Ki-67 allows to investigate the proliferative activity of tumor and is a clinically useful marker to characterize breast cancer. In this study, we have compared Ki-67 activity in 38 primary breast tumors and in their respective positive axillary lymph nodes (ALNs).
Methods. Immunohistochemistry with the monoclonal antibody against Ki-67 was performed in 38 nodes positive breast carcinomas and in their respective positive ALNs. Statistical analysis was performed with the Student's t-test (2-tailed) for equality of means.
Results. The proliferation index measured by Ki-67 expression was significatively higher (p < 0.02) in ALN than in the primary tumor (29.8% v.s. 21.8%).
Conclusion. These results strongly suggest a higher proliferation and perhaps aggressivity of metastatic neoplastic cells when compared with their respective primary tumor. Perhaps, in the future, these differences in proliferation behavior might be taken into account when considering the choice of the adjuvant therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosai J (ed): Ackerman's Surgical Pathology. Vol 1, 8th edn, Mosby, St Louis, 1996
Gerdes J, Lemke H, Baisch H: Cell cycle analysis of a cell proliferating associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715, 1984
McGurrin JF, Dorria Jr MI, Dawson PJ, Karrison T, Franklin WA: Assessment of tumor cell kinetics by immunohisto-chemistry in carcinoma of the breast. Cancer 15: 1744–1750, 1987
Veronese SM, Gambacorta M: Detection of Ki-67 proliferation rate in breast cancer: correlation with clinical and pathologic features. Am J Clin Pathol 95: 30–34, 1991
Charpin C, Audrac L, Vacheret H, Habib MC, van Devict MN: Multiparametric evaluation (SAMBA) of fractions (monoclonal Ki-67) in breast carcinoma tissue. Cancer Res 48: 4368–4374, 1988
Wrba F, Reiner A, MarKis-Ritzinger E, Holzner JH, Spona J: Prognostic significance of immunohistochemic parameters in breast carcinoma. Pathol Res Pract 83, 1988
Weikel W, Beck T, Mitze M, Knapstein PG: Immunohistochemical evaluation of growth fractions in human breast cancer using monoclonal antibody Ki-67. Breast Cancer Res Treat 18: 149–154, 1991
Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P: Proliferation index as a prognostic marker in breast cancer. Cancer 71: 3926–3931, 1993
Midulla C, De Iorio P, Nagar C, Pisani T, Cenci M, Valli C, Nofroni I, Vecchione A: Immunohistochemical expression of p3, nm23-HI, Ki-67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer. Anticancer Res 19: 4033–4038, 1999
Bloom H, Richardson W: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–377, 1957
Anaf V, El Nakadi I, Simon P, Englert Y, Peny MO, Fayt I, Noel JC: Sigmoid endometriosis and ovarian stimulation. Human Reprod 15: 790–794, 2000
Wood A, Hortobagyi G: Treatment of breast cancer. N Engl J Med 339: 974–984, 1998
Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M: The German Breast Cancer Study Group. Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer 37: 1123–1131, 2001
Goldhirsch A, Glick J, Gelber R, Coates A, Senn HJ: Meetings highlights: International consensus panel on the treatment of primary breast cancer. J Clinic Oncol 19: 3817–3827, 2001
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Buxant, F., Anaf, V., Simon, P. et al. Ki-67 Immunostaining Activity is Higher in Positive Axillary Lymph Nodes than in the Primary Breast Tumor. Breast Cancer Res Treat 75, 1–3 (2002). https://doi.org/10.1023/A:1016504129183
Issue Date:
DOI: https://doi.org/10.1023/A:1016504129183